BioTime Wins as Geron Exits Stem Cell Space and Arrowhead Fat Drug News Explodes
For years now, I've been telling you that Geron is not a serious player in the stem cell space. Financial and nonfinancial media, however, have inevitably treated the company as if it is the only really important stem cell company. I've told you repeatedly, in fact, that the company's technology for acquiring therapeutic stem cells is flawed and obsolete. Specifically, Geron's stem cell production technique is "heterogeneous differentiation." In other words, stem cells are allowed to differentiate into many thousands of stem cell types. Scientists attempt to isolate or "cherry pick" the right type of stem cells and multiply them into usable numbers.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.